Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
balugrastim
- Development stage
- Phase 3
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Balugrastim is a long-acting recombinant fusion protein composed of human serum albumin and granulocyte colony-stimulating factor (G-CSF), developed for the prevention of severe neutropenia in cancer patients receiving myelosuppressive chemotherapy. The fusion with albumin extends the half-life of G-CSF, allowing for once-per-cycle, fixed-dose subcutaneous administration. Balugrastim stimulates the production and function of neutrophils by acting as a granulocyte colony-stimulating factor replacement, thereby reducing the incidence and duration of chemotherapy-induced neutropenia and febrile neutropenia. It has demonstrated non-inferiority to pegfilgrastim in phase III clinical trials involving breast cancer patients undergoing chemotherapy[2][4][5][7].
- Brand names
- Egranli
- Other names
- balugrastim
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on balugrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on balugrastim.